AP 203
Alternative Names: AP-203Latest Information Update: 03 Aug 2022
Price :
$50 *
At a glance
- Originator AP Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Aug 2022 Preclinical trials in Solid tumours in Taiwan (IV) before August 2022 (AP Biosciences pipeline; August 2022)
- 01 Aug 2022 AP Biosciences plans a phase-I/II trial APT-CUBE for Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in December 2022 (IV, infusion) (NCT05473156)